EyePoint Pharmaceuticals, Inc.(EYPT) stock price and fundamentals

Biotechnology · Watertown, MA

$3.19+0.04 (+1.27%)

Delayed quote: Oct 6, 2026, 11:05 AM EDT

About EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.

Watertown, MA

214 employees

www.eyepoint.bio

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jay S. Duker

View full financials

Stock	Market Cap	Close Price	Price Change	TTM Total Return	5Y CAGR	10Y CAGR	Compare
1EYPT	$267.45M	$3.19	+1.27%	-76.90%	-21.68%	-20.02%	N/A
2OSUR	$265.73M	$3.86	-6.09%	+29.09%	-17.56%	-6.51%	vs EYPT
3EPRX	$265.50M	$7.93	+2.39%	+32.30%	N/A	N/A	vs EYPT
4PALI	$262.11M	$1.51	+3.42%	-8.78%	-76.02%	-71.24%	vs EYPT
5ACIU	$262.07M	$2.58	-4.98%	-31.95%	-16.03%	-16.61%	vs EYPT
6IKT	$261.43M	$1.98	-1.00%	+20.37%	-29.10%	N/A	vs EYPT

Period	Low	Avg	High	# Analysts
Quarter ending Sep 2026	$-1.06	$-0.91	$-0.67	7
Quarter ending Dec 2026	$-1.08	$-0.82	$-0.60	7
Quarter ending Mar 2027	$-0.59	$-0.59	$-0.59	2
Quarter ending Jun 2027	$-0.60	$-0.60	$-0.60	2

Period	Low	Avg	High	# Analysts
FY 2026	$-4.13	$-3.72	$-2.97	9
FY 2027	$-4.18	$-2.73	$-1.22	9

Period	Low	Avg	High	# Analysts
Quarter ending Sep 2026	$231154.00	$231154.00	$231154.00	7
Quarter ending Dec 2026	$301077.00	$301077.00	$301077.00	7
Quarter ending Mar 2027	$125000.00	$125000.00	$125000.00	3
Quarter ending Jun 2027	$125000.00	$125000.00	$125000.00	3

FY 2026	$1.56M	$1.72M	$2.08M	10
FY 2027	$6.15M	$17.93M	$29.71M	9

EyePoint Pharmaceuticals, Inc.(EYPT) stock price and fundamentals

Valuation

Yields

EYPT Price Chart

Business at a glance

EYPT Key Metrics

Total Return CAGR

EYPT Fundamental Charts

Revenue CAGR

EYPT Selected Revenue Disclosures

Product / business disclosures (FY 2024)

EYPT Earnings Preview

Similar-Size Sector Stocks

EYPT Competitors' Key Metrics

EYPT Charts

Valuation Charts

Performance Charts

Dividend Charts

CAGR Charts

Financial Statement Charts

Other Charts

Geographic disclosures (FY 2024)

EYPT Analyst Ratings

EYPT Analyst Estimates

Earnings Per Share (EPS) Estimates

Revenue Estimates